A Phase 3 interventional study of Ticagrelor and Clopidogrel in Acute Coronary Syndrome, sponsored by AstraZeneca. Completed at 672 sites in 44 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2012-03-13.
Sponsored by AstraZeneca · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 67 studies testing ticagrelor in Acute Coronary Syndrome — 6 open to participants now, 8 under way, 1 of them phase 3. Ticagrelor · Acute Coronary Syndrome.
Among the 67 studies testing ticagrelor in Acute Coronary Syndrome, this one is the 2nd largest by enrollment, is the only one that started in 2006, is one of 16 in phase 3, and was the 1st registered.
1,491 studies on the registry are indexed under Acute Coronary Syndrome; 273 are open to participants now.
Browse Acute Coronary Syndrome studies →6 of the 67 studies testing ticagrelor in Acute Coronary Syndrome are open now, in 7 countries. Recruiting first, the newest first:
Instituto de Investigación Sanitaria de la Fundación Jiménez Díaz · Sites in Ireland, Latvia, Norway and 2 more countries
Ages 18+
Cardiocentro Ticino · Sites in Switzerland
Ages 18+
Medical University of Gdansk · Sites in Poland
Ages 18+
Fu Wai Hospital, Beijing, China · Sites in China
Ages 18+
Shanghai Tong Ren Hospital · Sites in China
Ages 75+
By country, each count listing its studies:
Ticagrelor: first FDA approval 2011 (BRILINTA), first EMA approval 2010. What it is approved for, and how studies give it, is on its page →
Of the 196 Acute Coronary Syndrome studies recruiting now, 145 (74%) set no upper age limit and 19 (10%) stop at 75 or younger; 15 take children under 18; 15 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
67 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 2 · Phase 2 6 · Phase 3 17 · Phase 4 38
First in 2006; this study’s year is marked. 1 started in 2006.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 18,624 is above the median of 200 across 868 interventional studies indexed under Acute Coronary Syndrome.
Median enrollment 120 across the 67 interventional studies. Of the 45 that completed or were terminated, 13 (29%) have results posted.
This tab as a report to print or save as PDF → With an account.
9 of 67 have an industry lead sponsor. The 10 most frequent:
AstraZeneca is the lead sponsor of 3,503 studies on the registry; 273 are open to participants now.
Of its 369 completed or terminated interventional studies of FDA-regulated products, 178 (48%) have results posted.
36 studies in Acute Coronary Syndrome by AstraZeneca: none open now, none under way, none of them phase 3. Of 35 finished, 8 (23%) have results posted.
Among the 36 studies in Acute Coronary Syndrome by AstraZeneca, this one is the 2nd largest by enrollment of the 12 interventional ones that give a count, is one of 2 that started in 2006, is one of 5 in phase 3, and was the 3rd registered.
AstraZeneca’s Acute Coronary Syndrome studies by the year they started, since 2003.
None of the studies under way reaches primary completion within a year.
Among the 67 studies testing ticagrelor in Acute Coronary Syndrome, from their registry updates:
Nothing recorded among them since 2026-09-25.
Among AstraZeneca’s 36 in Acute Coronary Syndrome:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
Ticagrelor is a new, reversible binding, anti-platelet medication. Anti-platelet medications work to prevent the formation of blood clots. Ticagrelor is being developed as a treatment for patients with acute coronary syndrome (ACS). ACS is a term that is used to describe both heart attacks in progress or the imminent threat of a heart attack. ACS is usually caused by the formation of a blood clot in an artery that partially or totally blocks the blood supply to a portion of the heart muscle. Ticagrelor will be compared with clopidogrel to determine which drug, when either is used in conjunction with aspirin, is better at reducing deaths from vascular causes, future heart attacks and/or strokes in patients with ACS.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Oral treatment
Drug: Clopidogrel
Oral treatment
Drug: Ticagrelor
Ticagrelor (AZD6140) 90 mg twice daily dose (BD)
Also known as: AZD6140
Clopidogrel 75 mg once daily dose (ODD)
Also known as: Plavix®
Participants With Any Event From the Composite of Death From Vascular Causes, Myocardial Infarction (MI), and Stroke
Participants with death from vascular causes, MI, or stroke. If no event, censoring occurs at the earliest of patient withdrawal consent or date of scheduled withdrawal from therapy. Intention To Treat (ITT) analysis of whole population. Events were adjudicated by an endpoint committee.
Time frame: Randomization up to 12 months
Participants With Any Major Bleeding Event
Participants with major (fatal/life-threatening or other) bleed by a study protocol scale based on need for treatment, number of transfusions, hemoglobin decrease, and other factors. Events were adjudicated by an endpoint committee.
Time frame: First dosing up to 12 months
Participants With Any Event From the Composite of Death From Vascular Causes, MI, and Stroke for the Subgroup of Patients With Intent for Invasive Management at Randomization
Participants with death from vascular causes, MI, or stroke. If no event, censoring occurs at the earliest of patient withdrawal consent or date of scheduled withdrawal from therapy. ITT analysis of intent for invasive management population. Events were adjudicated by an endpoint committee.
Time frame: Randomization up to 12 months
Participants With Any Event From the Composite of All-cause Mortality, MI, and Stroke
Participants with death from any cause, MI, or stroke. If no event, censoring occurs at the earliest of patient withdrawal of consent or date of scheduled withdrawal from therapy. ITT analysis of whole population. Events were adjudicated by an endpoint committee.
Time frame: Randomization up to 12 months
Participants With Any Event From the Composite of Death From Vascular Causes, MI (Including Silent), Stroke, Recurrent Ischemia, Transient Ischemic Attack (TIA) and Other Arterial Thrombotic Events.
Participants with death from vascular causes, MI, stroke, recurrent ischemia, or other thrombotic events. If no event, censoring occurs at the earliest of patient withdrawal consent or date of scheduled withdrawal from therapy. ITT analysis of whole population. Events were adjudicated.
Time frame: Randomization up to 12 months
Participants With MI Event
Participants with MI event. If no event, censoring occurs at the earliest of patient withdrawal consent or date of scheduled withdrawal from therapy. ITT (intention to treat) analysis of whole population. Events were adjudicated by an endpoint committee.
Time frame: Randomization up to 12 months
Participants With Death From Vascular Causes
Participants with death from vascular causes. If no event, censoring occurs at the earliest of patient withdrawal consent or date of scheduled withdrawal from therapy. ITT (intention to treat) analysis of whole population. Events were adjudicated by an endpoint committee.
Time frame: Randomization up to 12 months
Participants With Stroke
Participants with stroke. If no event, censoring occurs at the earliest of patient withdrawal consent or date of scheduled withdrawal from therapy. ITT (intention to treat) analysis of whole population. Events were adjudicated by an endpoint committee.
Time frame: Randomization up to 12 months
Participants With Death From Any Cause
Participants with death from any cause. If no event, censoring occurs at the earliest of patient withdrawal consent or date of scheduled withdrawal from therapy. ITT (intention to treat) analysis of whole population. Events were adjudicated by an endpoint committee.
Time frame: Randomization up to 12 months
Participants With Non-CABG (Coronary Artery Bypass Graft) Related Major Bleeding
Participants with non CABG related major (fatal/life-threatening or other) bleed by a study protocol scale based on need for treatment, number of transfusions, hemoglobin decrease, and other factors. Events were adjudicated by an endpoint committee.
Time frame: First dosing up to 12 months
Participants With Major or Minor Bleeding
Participants with major (fatal/life-threatening or other) or minor bleed by a study protocol scale based on need for treatment, number of transfusions, hemoglobin decrease, and other factors. Events were adjudicated by an endpoint committee.
Time frame: First dosing up to 12 months
Participants With Non-procedural Major Bleeding
Participants with non-procedural major bleed by a study protocol scale based on need for treatment, number of transfusions, hemoglobin decrease, and other factors. Events were adjudicated by an endpoint committee.
Time frame: First dosing up to 12 months
Participants With Coronary Artery Bypass Graft (CABG) Major Bleeding
Participants with a major CABG-related bleed by a study protocol scale based on need for treatment, number of transfusions, hemoglobin decrease, and other factors. All CABG surgeries were submitted for adjudication by an endpoint committee as potential bleeds.
Time frame: First dosing up to 12 months
Participants With Coronary Artery Bypass Graft (CABG) Major Fatal/Life-threatening Bleeding
Number of participants with a major fatal/life-threatening CABG-related bleed by a study protocol scale based on need for treatment, number of transfusions, hemoglobin decrease, and other factors. All CABG surgeries were submitted for adjudication by an endpoint committee as potential bleeds.
Time frame: First dosing up to 12 months
Participants With Ventricular Pauses of Greater Than or Equal to 3 Seconds in Patients Monitored by Holter 24-hour ECG Recorders for 1 Week Following Randomization
Number of participants who were observed to have at least 1 ventricular pause of at least 3 seconds. Population is all patients who were observed over 2 week-long periods. Pauses were flagged algorithmically and confirmed by Thrombolysis in Myocardial Infarction (TIMI) group cardiologists.
Time frame: 1-week period following randomization
Participants With Ventricular Pauses of Greater Than or Equal to 3 Seconds in Patients Monitored by Holter 24 Hour ECG Recorders for 1 Week at 1 Month Following Randomization
Number of participants who were observed to have at least 1 ventricular pause of at least 3 seconds. Population is all patients who were observed over 2 week-long periods. Pauses were flagged algorithmically and confirmed by TIMI cardiologists.
Time frame: 1-week period following randomization
The first participant was enrolled on 11 October 2006 and the last participant completed the study on 27 February 2009. Study participants were randomized from 855 centers in 43 countries.
| Milestone | TICAGRELOR | CLOPIDOGREL |
|---|---|---|
| Started | 9333 | 9291 |
| Completed | 9026 | 9036 |
| Not completed | 307 | 255 |
| Withdrew: Protocol violation | 7 | 2 |
| Withdrew: Withdrawal by subject | 296 | 249 |
| Withdrew: Reason unknown | 2 | 4 |
| Withdrew: Lost to follow-up | 2 | 0 |
Participants with death from vascular causes, MI, or stroke. If no event, censoring occurs at the earliest of patient withdrawal consent or date of scheduled withdrawal from therapy. Intention To Treat (ITT) analysis of whole population. Events were adjudicated by an endpoint committee.
| Participants | TICAGRELOR | CLOPIDOGREL |
|---|---|---|
| Participants With Any Event From the Composite of Death From Vascular Causes, Myocardial Infarction (MI), and Stroke | 864 | 1014 |
Participants with major (fatal/life-threatening or other) bleed by a study protocol scale based on need for treatment, number of transfusions, hemoglobin decrease, and other factors. Events were adjudicated by an endpoint committee.
| Participants | TICAGRELOR | CLOPIDOGREL |
|---|---|---|
| Participants With Any Major Bleeding Event | 961 | 929 |
Participants with death from vascular causes, MI, or stroke. If no event, censoring occurs at the earliest of patient withdrawal consent or date of scheduled withdrawal from therapy. ITT analysis of intent for invasive management population. Events were adjudicated by an endpoint committee.
| Participants | TICAGRELOR | CLOPIDOGREL |
|---|---|---|
| Participants With Any Event From the Composite of Death From Vascular Causes, MI, and Stroke for the Subgroup of Patients With Intent for Invasive Management at Randomization | 569 | 668 |
Participants with death from any cause, MI, or stroke. If no event, censoring occurs at the earliest of patient withdrawal of consent or date of scheduled withdrawal from therapy. ITT analysis of whole population. Events were adjudicated by an endpoint committee.
| Participants | TICAGRELOR | CLOPIDOGREL |
|---|---|---|
| Participants With Any Event From the Composite of All-cause Mortality, MI, and Stroke | 901 | 1065 |
Participants with death from vascular causes, MI, stroke, recurrent ischemia, or other thrombotic events. If no event, censoring occurs at the earliest of patient withdrawal consent or date of scheduled withdrawal from therapy. ITT analysis of whole population. Events were adjudicated.
| Participants | TICAGRELOR | CLOPIDOGREL |
|---|---|---|
| Participants With Any Event From the Composite of Death From Vascular Causes, MI (Including Silent), Stroke, Recurrent Ischemia, Transient Ischemic Attack (TIA) and Other Arterial Thrombotic Events. | 1290 | 1456 |
Participants with MI event. If no event, censoring occurs at the earliest of patient withdrawal consent or date of scheduled withdrawal from therapy. ITT (intention to treat) analysis of whole population. Events were adjudicated by an endpoint committee.
| Participants | TICAGRELOR | CLOPIDOGREL |
|---|---|---|
| Participants With MI Event | 504 | 593 |
Participants with death from vascular causes. If no event, censoring occurs at the earliest of patient withdrawal consent or date of scheduled withdrawal from therapy. ITT (intention to treat) analysis of whole population. Events were adjudicated by an endpoint committee.
| Participants | TICAGRELOR | CLOPIDOGREL |
|---|---|---|
| Participants With Death From Vascular Causes | 353 | 442 |
Participants with stroke. If no event, censoring occurs at the earliest of patient withdrawal consent or date of scheduled withdrawal from therapy. ITT (intention to treat) analysis of whole population. Events were adjudicated by an endpoint committee.
| Participants | TICAGRELOR | CLOPIDOGREL |
|---|---|---|
| Participants With Stroke | 125 | 106 |
Participants with death from any cause. If no event, censoring occurs at the earliest of patient withdrawal consent or date of scheduled withdrawal from therapy. ITT (intention to treat) analysis of whole population. Events were adjudicated by an endpoint committee.
| Participants | TICAGRELOR | CLOPIDOGREL |
|---|---|---|
| Participants With Death From Any Cause | 399 | 506 |
Participants with non CABG related major (fatal/life-threatening or other) bleed by a study protocol scale based on need for treatment, number of transfusions, hemoglobin decrease, and other factors. Events were adjudicated by an endpoint committee.
| Participants | TICAGRELOR | CLOPIDOGREL |
|---|---|---|
| Participants With Non-CABG (Coronary Artery Bypass Graft) Related Major Bleeding | 362 | 306 |
Participants with major (fatal/life-threatening or other) or minor bleed by a study protocol scale based on need for treatment, number of transfusions, hemoglobin decrease, and other factors. Events were adjudicated by an endpoint committee.
| Participants | TICAGRELOR | CLOPIDOGREL |
|---|---|---|
| Participants With Major or Minor Bleeding | 1339 | 1215 |
Participants with non-procedural major bleed by a study protocol scale based on need for treatment, number of transfusions, hemoglobin decrease, and other factors. Events were adjudicated by an endpoint committee.
| Participants | TICAGRELOR | CLOPIDOGREL |
|---|---|---|
| Participants With Non-procedural Major Bleeding | 235 | 180 |
Participants with a major CABG-related bleed by a study protocol scale based on need for treatment, number of transfusions, hemoglobin decrease, and other factors. All CABG surgeries were submitted for adjudication by an endpoint committee as potential bleeds.
| Participants | TICAGRELOR | CLOPIDOGREL |
|---|---|---|
| Participants With Coronary Artery Bypass Graft (CABG) Major Bleeding | 619 | 654 |
Number of participants with a major fatal/life-threatening CABG-related bleed by a study protocol scale based on need for treatment, number of transfusions, hemoglobin decrease, and other factors. All CABG surgeries were submitted for adjudication by an endpoint committee as potential bleeds.
| Participants | TICAGRELOR | CLOPIDOGREL |
|---|---|---|
| Participants With Coronary Artery Bypass Graft (CABG) Major Fatal/Life-threatening Bleeding | 329 | 341 |
Number of participants who were observed to have at least 1 ventricular pause of at least 3 seconds. Population is all patients who were observed over 2 week-long periods. Pauses were flagged algorithmically and confirmed by Thrombolysis in Myocardial Infarction (TIMI) group cardiologists.
| Participants | TICAGRELOR | CLOPIDOGREL |
|---|---|---|
| Participants With Ventricular Pauses of Greater Than or Equal to 3 Seconds in Patients Monitored by Holter 24-hour ECG Recorders for 1 Week Following Randomization | 84 | 51 |
Number of participants who were observed to have at least 1 ventricular pause of at least 3 seconds. Population is all patients who were observed over 2 week-long periods. Pauses were flagged algorithmically and confirmed by TIMI cardiologists.
| Participants | TICAGRELOR | CLOPIDOGREL |
|---|---|---|
| Participants With Ventricular Pauses of Greater Than or Equal to 3 Seconds in Patients Monitored by Holter 24 Hour ECG Recorders for 1 Week at 1 Month Following Randomization | 21 | 16 |
Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| TICAGRELOR | — | — | — |
| CLOPIDOGREL | — | — | — |
| Event | TICAGRELOR | CLOPIDOGREL |
|---|---|---|
| Cardiac FailureCardiac disorders | 122/9333 | 129/9291 |
| Non-Cardiac Chest PainGeneral disorders | 101/9333 | 103/9291 |
| PneumoniaInfections and infestations | 69/9333 | 95/9291 |
| Cerebrovascular AccidentNervous system disorders | 75/9333 | 50/9291 |
| DyspnoeaRespiratory, thoracic and mediastinal disorders | 75/9333 | 50/9291 |
| Atrial FibrillationCardiac disorders | 70/9333 | 68/9291 |
| Cardiogenic ShockCardiac disorders | 60/9333 | 66/9291 |
| Ventricular FibrillationCardiac disorders | 48/9333 | 64/9291 |
| Chest PainGeneral disorders | 54/9333 | 63/9291 |
| Thrombosis In DeviceInjury, poisoning and procedural complications | 35/9333 | 57/9291 |
| Event | TICAGRELOR | CLOPIDOGREL |
|---|---|---|
| DyspnoeaRespiratory, thoracic and mediastinal disorders | 1106/9333 | 623/9291 |
| HeadacheNervous system disorders | 621/9333 | 565/9291 |
| EpistaxisRespiratory, thoracic and mediastinal disorders | 566/9333 | 317/9291 |
| CoughRespiratory, thoracic and mediastinal disorders | 490/9333 | 467/9291 |
| Age Continuous(years) | TICAGRELOR | CLOPIDOGREL | Total |
|---|---|---|---|
| Mean | 62.1 ± 11.21 | 62.3 ± 11.21 | 62.2 ± 22.42 |
| Sex: Female, Male(Participants) | TICAGRELOR | CLOPIDOGREL | Total |
|---|---|---|---|
| Female | 2655 | 2633 | 5288 |
| Male | 6678 | 6658 | 13336 |
Showing the first 100 of 672 sites across 44 countries. Choose a country and city above to see the rest.
The record gives a start of Oct 2006, a primary completion of Mar 2009 and a completion of Mar 2009. It does not say whether these dates are actual or estimated.
Results were first posted in Mar 2012, 3 years after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Feb 2012. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Ticagrelor